Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Convalescent Plasma and Camostat in Early COVID-19
NCT04681430Phase 2Completed
- Sponsor
- Heinrich Heine University Düsseldorf
- Start
- Jan 2021
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of convalescent plasma (Heinrich-Heine University, Duesseldorf) and camostat mesilate in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Heinrich Heine University Düsseldorf. Primary endpoints: Cumulative number of individuals who progressed to or beyond category 4b on the modified WHO COVID-19 ordinal scale at 28 days and WHO ordinal Covid-19 scale at 28 days. Started Jan 2021; status: completed.
02
Drugs
convalescent plasma (Heinrich-Heine University, Duesseldorf)camostat mesilate
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04681430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04681430.